Coherus BioSciences Inc. (CHRS) Plunges 5.58% on January 16

Coherus BioSciences Inc. (CHRS) Plunges 5.58% on January 16

Coherus BioSciences Inc. (CHRS) had a rough trading day for Wednesday January 16 as shares tumbled 5.58%, or a loss of $-0.68 per share, to close at $11.51. After opening the day at $12.17, shares of Coherus BioSciences Inc. traded as high as $12.22 and as low as $11.40. Volume was 537,390 shares over 4,116 trades, against an average daily volume of n/a shares and a total float of 68.02 million.

As a result of the decline, Coherus BioSciences Inc. now has a market cap of $782.97 million. In the last year, shares of Coherus BioSciences Inc. have traded between a range of $20.66 and $8.32, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

Coherus BioSciences is a biotechnology company that develops biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Coherus’ commercialization partnerships include global pharmaceutical companies in Europe, Asia, and Latin America. The company seeks to ensure successful drug development and manufacturing under very aggressive timelines. Coherus generates the vast majority of its revenue in the United States.

Coherus BioSciences Inc. is based out of Redwood City, CA and has some 182 employees. Its CEO is Dennis M. Lanfear.

Share:
Scroll Up
error: Content is protected !!